BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Puligedda RD, Vigdorovich V, Kouiavskaia D, Kattala CD, Zhao JY, Al-Saleem FH, Chumakov K, Sather DN, Dessain SK. Human IgA Monoclonal Antibodies That Neutralize Poliovirus, Produced by Hybridomas and Recombinant Expression. Antibodies (Basel) 2020;9:E5. [PMID: 32121092 DOI: 10.3390/antib9010005] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 2.5] [Reference Citation Analysis]
Number Citing Articles
1 Falci Finardi N, Y-h. Teh A, K-c. Ma J. Engineering Secretory IgA against Infectious Diseases. Immunosuppression and Immunomodulation [Working Title] 2022. [DOI: 10.5772/intechopen.108426] [Reference Citation Analysis]
2 Langel S, Steppe J, Chang J, Travieso T, Webster H, Otero C, Williamson L, Crowe J, Greenberg H, Wu H, Hornik C, Mansouri K, Edwards R, Stalls V, Acharya P, Blasi M, Permar S. Protective Transfer: Maternal passive immunization with a rotavirus-neutralizing dimeric IgA protects against rotavirus disease in suckling neonates.. [DOI: 10.1101/2021.09.21.461116] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
3 DiMuzio JM, Heimbach BC, Howanski RJ, Dowling JP, Patel NB, Henriquez N, Nicolescu C, Nath M, Polley A, Bingaman JL, Smith T, Harman BC, Robinson MK, Morin MJ, Nikitin PA. Unbiased interrogation of memory B cells from convalescent COVID-19 patients reveals a broad antiviral humoral response targeting SARS-CoV-2 antigens beyond the spike protein. Vaccine X 2021;8:100098. [PMID: 33937741 DOI: 10.1016/j.jvacx.2021.100098] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 5.0] [Reference Citation Analysis]
4 Dimuzio JM, Heimbach BC, Howanski RJ, Dowling JP, Patel NB, Henriquez N, Nicolescu C, Nath M, Polley A, Bingaman JL, Smith T, Harman BC, Robinson MK, Morin MJ, Nikitin PA. Unbiased interrogation of memory B cells from convalescent COVID-19 patients reveals a broad antiviral humoral response targeting SARS-CoV-2 antigens beyond the spike protein.. [DOI: 10.1101/2021.01.27.428534] [Reference Citation Analysis]
5 van Tetering G, Evers M, Chan C, Stip M, Leusen J. Fc Engineering Strategies to Advance IgA Antibodies as Therapeutic Agents. Antibodies (Basel) 2020;9:E70. [PMID: 33333967 DOI: 10.3390/antib9040070] [Cited by in Crossref: 13] [Cited by in F6Publishing: 14] [Article Influence: 6.5] [Reference Citation Analysis]
6 Cnudde T, Lakhrif Z, Bourgoin J, Boursin F, Horiot C, Henriquet C, di Tommaso A, Juste MO, Jiacomini IG, Dimier-Poisson I, Pugnière M, Mévélec MN, Aubrey N. Exploration and Modulation of Antibody Fragment Biophysical Properties by Replacing the Framework Region Sequences. Antibodies (Basel) 2020;9:E9. [PMID: 32326443 DOI: 10.3390/antib9020009] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]